Skip to main content

Kidney Summit 2022

CME/CNE-certified, ABIM MOC/MIPS-eligible Activity

Click here to complete your registration.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

Wednesday, November 30, 2022
3:00 - 4:30 PM ET (2:00 - 3:30 PM CT/ 12:00 - 1:30 PM PT)

Topic 1: Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs
Welcome and Introductions
Pathophysiology of Anemia in Chronic Kidney Disease
Health Outcomes, Quality of Life, and Functioning in Patients with Chronic Kidney Disease and Anemia
Current Management of Anemia in Chronic Kidney Disease
Agents in Late-Stage Development for Managing Anemia in Chronic Kidney Disease
Q&A Session
AKF Discussion

Topic 2: 2023 Reimbursement Renal Care Changes
(Presentation topic #2  is not considered mandatory for learner completion to receive credit. Learners will receive access to the post-test and evaluation after completing the first hour of content and will not receive credit for the additional presentations. These additional presentations are not supported by any grantor or commercial support.)

Anemia in CKD is associated with increased risk of CKD progression, poor CV outcomes, decreased health-related quality of life, and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events.

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs will familiarize nephrology clinicians with the etiology of anemia in CKD, the effects on health outcomes, quality of life, and function, advantages and limitations of current management strategies and the economic advantages of their use, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.


Christine Chmielewski, MS, CRNP, ANP-BC, CNN-NP
Nephrology Nurse Practitioner
Jefferson Renal Associates
Thomas Jefferson University Hospital
Philadelphia, PA

Matthew R. Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, MD

Jay B. Wish, MD
Professor of Clinical Medicine
Indiana University School of Medicine
Chief Medical Officer for Out-Patient Dialysis
Indiana University Health
Indianapolis, IN


This activity is intended for nephrology clinicians, including nephrologists and nephrology nurses, who are clinicians responsible for managing patients with chronic kidney disease.

At the conclusion of this activity, participants should be able to:
  • Summarize the etiology of anemia in chronic kidney disease
  • Describe the negative effects of anemia on health outcomes, quality of life, and functioning for patients with chronic kidney disease
  • Evaluate the advantages and limitations of current management strategies for anemia in chronic kidney disease
  • Assess the mechanism of action and efficacy and safety data for agents in late-stage development for the management of anemia of chronic kidney disease

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this live activity/enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about accreditation of this activity, please email:

 USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hours may be earned by learners who successfully complete this continuing nursing education activity. USF Health, the accredited provider, acknowledges Rockpointe as the joint provider in the planning and execution of this CNE activity.
This activity is awarded 1.0 ANCC pharmacotherapeutic contact hours.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is USF Health's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Participant’s MOC Points. No MOC certificates will be provided. Participants with questions regarding their Points, should contact USF Health at cpdsupport@usf. edu

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).


USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

The faculty, authors, and content developers reported the following relevant financial relationships with ineligible companies:
Christine Chmielewski, NP:  Advisory Board or Panel: Vifor (Relationship Terminated) Consultant: Rockwell (Relationship Terminated) Speaker’s Bureau: AstraZeneca, Vifor

Jay Wish, MD:  Advisory Board or Panel: Fibrogen, Akebia, GSK, Vifor Pharma,  AstraZeneca, Otsuka, Amgen, Rockwell Medical, CSL Behring(Relationships Terminated) Speaker's Bureau: AstraZeneca, Akebia (Relationships Terminated)

Matthew Weir, MD: Advisory Board or Panel: Boehringer Ingelheim, Novo Nordisk, Bayer, Merck, AstraZeneca, GSK, Janssen, Vifor, and Akebia

Robert Blaser: No relevant financial relationships to disclose

The planners and mangers reported the following relevant financial relationships with ineligible companies:
Terry A. Glauser, MD, MPH: No relevant financial relationships to disclose

USF Health OCPD Staff: No relevant financial relationships to disclose

The Nurse Planner and content reviewer report the following relevant financial relationships with ineligible companies:
Alicia Ann Canalejo, MSN, ARNP-C: No relevant financial relationships to disclose


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.


  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later
SOFTWARE REQUIREMENTS DSL/cable (wired connection recommended)

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times. The second hour is not required to obtain CME/CNE Credit or MOC points. 

Jointly provided by USF Health and Rockpointe

In Collaboration with 

This educational activity is supported by an educational grant from GlaxoSmithKline.

Topic 2: 2023 Reimbursement Renal Care Changes
Robert Blaser
Director of Public Policy
Renal Physicians Association
Rockville, MD

PCME Privacy Policy